The company's financial stability is under significant pressure, with total equity plummeting from $349.1 million in 2023Q4 to $4.4 million in 2026Q1, while the debt-to-equity ratio has surged to 16.33.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 |
|---|
| Total Current Assets | 128.07M | 163.9M | 289.31M | 340.83M | 356.75M | 507.31M | 419.09M | 463.84M | 374.78M | 332.2M | 187.18M | 144.99M | 10.72M | 2.09M |
| Cash & Short-Term Investments | 123.65M | 146.65M | 269.91M | 323.11M | 344.27M | 499.85M | 402.11M | 457.14M | 368.95M | 329.14M | 185.32M | 143.18M | 10.62M | 2.01M |
| Cash Only | 123.65M | 146.65M | 131.54M | 123.65M | 141.52M | 203.52M | 139.68M | 238.18M | 134.78M | 146.63M | 185.32M | 143.18M | 10.62M | 2.01M |
| Short-Term Investments | 0 | 0 | 138.37M | 199.46M | 202.75M | 296.33M | 262.43M | 218.96M | 234.18M | 182.51M | 0 | 0 | 0 | 0 |
| Accounts Receivable | 2.59M | 15.18M | 16.27M | 10.19M | 5.14M | 267K | 6.05M | 418K | 30K | 679K | 88K | 1.02M | 0 | 0 |
| Days Sales Outstanding | 62.46 | 136.7 | 183.73 | 47.59 | 95.27 | 3.82 | 24.33 | 7.43 | 0.34 | 18.05 | 5.31 | 228.32 | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.92M | 1.86M | 1.66M | 780K | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | 11.75 | 8.18 | 10.65 | 15.11 | - | - |
| Other Current Assets | 1.83M | 2.07M | 3.14M | 7.53M | 7.33M | 0 | 0 | 6.29M | 0 | 517K | 110K | 326K | 0 | 72K |
| Total Non-Current Assets | 21.27M | 22.64M | 52.27M | 158.32M | 157.57M | 170.17M | 153.51M | 45.04M | 45.61M | 41.06M | 42M | 4.38M | 1.47M | 392K |
| Property, Plant & Equipment | 18.3M | 19.66M | 47.05M | 45.71M | 59.22M | 43.29M | 39.15M | 39.65M | 40.23M | 39.44M | 40.38M | 2.13M | 1.11M | 52K |
| Fixed Asset Turnover | 1.86x | 2.06x | 0.69x | 1.71x | 0.33x | 0.59x | 2.32x | 0.52x | 0.79x | 0.35x | 0.15x | 0.76x | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 8.04M | 2.7M | 0 | 104.02M | 93.1M | 120.07M | 109.66M | 3.67M | 5.38M | 1.62M | 1.62M | 0 | 0 | 0 |
| Other Non-Current Assets | 306K | 276K | 5.22M | 8.59M | 5.25M | 6.81M | 4.7M | 1.73M | 0 | 0 | 0 | 2.25M | 360K | 340K |
| Total Assets | 149.34M | 186.53M | 341.59M | 499.15M | 514.32M | 677.48M | 572.6M | 508.88M | 420.39M | 373.26M | 229.18M | 149.36M | 12.19M | 2.48M |
| Asset Turnover | 0.21x | 0.22x | 0.09x | 0.16x | 0.04x | 0.04x | 0.16x | 0.04x | 0.08x | 0.04x | 0.03x | 0.01x | - | - |
| Asset Growth % | -172.43% | -45.39% | -31.57% | -2.95% | -24.08% | 18.32% | 12.52% | 21.05% | 12.63% | 62.87% | 53.44% | 1125.49% | 391.25% | - |
| Total Current Liabilities | 39.78M | 46.25M | 77.22M | 63.22M | 60.11M | 46.88M | 58.21M | 59.96M | 35.9M | 36.71M | 33.08M | 6.92M | 6.16M | 2.13M |
| Accounts Payable | 4.33M | 2.6M | 5.49M | 8.27M | 9.51M | 5.05M | 6.41M | 5.84M | 5.33M | 4.02M | 4.64M | 1.38M | 2.6M | 404K |
| Days Payables Outstanding | 3.18K | - | - | 497.72 | 547.82 | 364.78 | 14.8 | 22.01 | 21.45 | 17.64 | 29.72 | 26.75 | 186.71 | 92.74 |
| Short-Term Debt | 14.2M | 11.03M | 0 | 12M | 0 | 0 | 0 | 0 | 0 | 7.5M | 10M | 0 | 67K | 0 |
| Deferred Revenue (Current) | 103.71M | 44.51M | 11.22M | 8.22M | 8.22M | 11.33M | 20.94M | 23.51M | 15.71M | 13.24M | 26M | 88K | 1.69M | 0 |
| Other Current Liabilities | 18.47M | -11.9M | 21.99M | -723K | 10.14M | 10.16M | 5.32M | 19.83M | 9.66M | 8.24M | 1M | 4.06M | 1.91M | 993K |
| Current Ratio | 3.22x | 3.54x | 3.75x | 5.39x | 5.94x | 10.82x | 7.20x | 7.74x | 10.44x | 9.05x | 5.66x | 20.94x | 1.74x | 0.98x |
| Quick Ratio | 3.22x | 3.54x | 3.75x | 5.39x | 5.94x | 10.82x | 7.20x | 7.74x | 10.36x | 9.00x | 5.61x | 20.82x | 1.74x | 0.98x |
| Cash Conversion Cycle | -3.12K | - | - | - | - | - | - | - | -9.36 | 8.59 | -13.77 | 216.68 | - | - |
| Total Non-Current Liabilities | 105.15M | 113M | 130.09M | 86.84M | 93.53M | 76.96M | 120.81M | 186.49M | 148.32M | 128.47M | 61.49M | 225.55M | 21.32M | 2.12M |
| Long-Term Debt | 47.18M | 53.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 199.91M | 344K | 2.11M |
| Capital Lease Obligations | 51.22M | 12.07M | 20.38M | 24.37M | 32.86M | 16.07M | 19.32M | 23.28M | 32.42M | 33.43M | 35.1M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 380K | 289K | 0 | 0 |
| Other Non-Current Liabilities | 2.87M | 2.81M | 3.07M | 1.8M | 0 | 0 | 27.5M | 1K | 293K | 317K | 396K | 316K | 20.98M | 5K |
| Total Liabilities | 144.93M | 159.25M | 207.31M | 150.06M | 153.64M | 123.84M | 179.02M | 246.45M | 184.22M | 165.18M | 94.58M | 232.48M | 27.48M | 4.24M |
| Total Debt | 71.97M | 76.71M | 35.03M | 48.54M | 43.95M | 26.38M | 26.14M | 29.08M | 32.42M | 33.43M | 35.1M | 199.91M | 411K | 2.11M |
| Net Debt | -51.67M | -69.94M | -96.51M | -75.11M | -97.58M | -177.14M | -113.55M | -209.1M | -102.36M | -113.2M | -150.23M | 56.73M | -10.21M | 99K |
| Debt / Equity | 16.33x | 2.81x | 0.26x | 0.14x | 0.12x | 0.05x | 0.07x | 0.11x | 0.14x | 0.16x | 0.26x | - | - | - |
| Debt / EBITDA | -0.65x | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.46x | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | 91.80x | -24.94x | - | - | - | - | - | - | - | -122.03x | - | -508.79x | -374.21x | - |
| Total Equity | 4.41M | 27.29M | 134.27M | 349.1M | 360.68M | 553.64M | 393.59M | 262.44M | 236.16M | 208.08M | 134.61M | -83.11M | -15.29M | -1.76M |
| Equity Growth % | -356.69% | -79.68% | -61.54% | -3.21% | -34.85% | 40.67% | 49.97% | 11.13% | 13.5% | 54.58% | 261.95% | -443.51% | -767.39% | - |
| Book Value per Share | 0.05 | 0.31 | 1.63 | 4.60 | 5.25 | 8.19 | 6.72 | 5.25 | 5.01 | 5.16 | 4.18 | -2.33 | -5.97 | -0.06 |
| Total Shareholders' Equity | 4.41M | 27.29M | 134.27M | 349.1M | 360.68M | 553.64M | 393.59M | 262.44M | 236.16M | 208.08M | 134.61M | -83.11M | -15.29M | -1.76M |
| Common Stock | 10K | 10K | 8K | 8K | 7K | 7K | 6K | 5K | 5K | 4K | 4K | 0 | 0 | 0 |
| Retained Earnings | -1.65B | -1.63B | -1.47B | -1.23B | -1.08B | -857.7M | -665.2M | -549.22M | -416.28M | -305.85M | -185.53M | -88.35M | -15.45M | -1.76M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 268K | 198K | -3.6M | -493K | -46K | 107K | -29K | -76K | -229.18M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Liquidity and dilution risk
As reported in recent financial statements, Editas Medicine's total assets have declined from $499.2 million in 2023Q4 to $149.3 million in 2026Q1, reflecting a rapid depletion of resources as the company funds its clinical development programs without a sustainable, recurring revenue stream to replenish its capital base.
The consistent downward trend in total assets suggests that the company is consuming its primary capital reserves to sustain operations. This trajectory indicates that the business model remains in a state of contraction, where the lack of commercial-stage revenue forces a reliance on asset liquidation to meet ongoing R&D obligations.
Based on the provided balance sheet data, the company's debt-to-equity ratio has surged from 0.14 in 2023Q4 to 16.33 in 2026Q1, indicating that the firm is increasingly relying on debt financing to bridge its funding gap as equity value is eroded by persistent operating losses.
The sharp increase in leverage appears to be a necessity-driven response to dwindling cash reserves rather than a strategic capital allocation decision. Investors should monitor this trend closely, as the high debt-to-equity ratio may limit future financing flexibility and increase the risk of insolvency if clinical milestones are not met.
According to quarterly filings, the company's cash position has fluctuated significantly, dropping to $123.6 million in 2026Q1, which, when viewed alongside the current ratio of 3.22, suggests that while short-term obligations are covered, the runway for continued clinical operations is rapidly narrowing without further capital infusion.
The volatility in cash levels highlights the company's dependence on lumpy milestone payments to maintain liquidity. The current liquidity profile appears adequate for the immediate term, but the lack of consistent cash generation suggests that the company remains vulnerable to shocks in the biotechnology funding environment.
As evidenced by the decline in total equity from $349.1 million in 2023Q4 to a mere $4.4 million in 2026Q1, the company's book value has been severely impacted by accumulated deficits, which now total approximately $1.7 billion according to the latest reported figures.
The erosion of equity underscores the significant value destruction associated with the company's long-term R&D investment cycle. This trend suggests that shareholders face a high risk of further dilution, as the company may be forced to issue additional equity to stabilize its balance sheet and fund future clinical trials.
Quick answers to the most common questions about buying EDIT stock.
As of 2025, Editas Medicine, Inc. (EDIT) had total assets of $186.5M including $163.9M in current assets.
Editas Medicine, Inc. (EDIT) carries total debt of $76.7M, offset by $146.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Editas Medicine, Inc. (EDIT) has total shareholders' equity (book value) of $27.3M ($0.31 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Editas Medicine, Inc. (EDIT) reported a current ratio of 3.54x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.